# 4J Therapeutics Inc.

Canonical: https://abierto.us/vendors/4j-therapeutics-inc-szcgv7lqjkr4

- UEI: SZCGV7LQJKR4
- CAGE: 9DFF0
- Location: Palo Alto, CA
- Awards in window: 1 (4 transactions), $31,886,690 obligated, January 17, 2025 to August 21, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $31,886,690

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $31,886,690

## Competition

- Full and Open Competition: 1 awards

## Largest awards

- 75A50124C00052 (definitive contract): $31,886,690, Barda - Aspr / Daappo / Barda DCMA. The Purpose of This Bilateral Modification Is to Exercise Option 1 Clin 0002 to Conduct Non-Clinical Studies, 2ND NON-GLP Tox; Efficacy/Off-Target Studies and Update Article C.1. Statement of Work Dated January 10, 2025. the Option Period of Performa. https://www.usaspending.gov/award/CONT_AWD_75A50124C00052_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/4j-therapeutics-inc-szcgv7lqjkr4.